Kornimate/medical-research-clean huggingface dataset:
battlefield acupuncture for low back pain

Conditions: Low Back Pain; Chronic Low Back Pain

Summary: the purpose of this study is to determine the effect of battlefield acupuncture (bfa) on outcomes for pain, sleep, and physical activity level in an active duty military sample with subacute or chronic lower back pain (lbp). bfa is a form of auricular acupuncture (aa) that has been implemented in many department of defense (dod)/veterans affairs (va) medical settings to alleviate acute or chronic pain. bfa uses five predetermined locations in a defined sequence to place semi-permanent needles in the ear. subacute lower back pain is pain that has persistently lasted from four to twelve weeks. chronic lower back pain is pain that lasts more than 12 weeks. hypothesis 1: participants with subacute or chronic lbp will have reduced pain using bfa as compared to placebo. hypothesis 2: participants with subacute or chronic lbp will have improved physical activity using bfa as compared to placebo. hypothesis 3: participants with subacute or chronic lbp will have improved sleep quality as compared to placebo. the secondary study aims are: 1. to explore the effects of bfa two weeks following the treatment for lbp. 1. do positive outcomes appreciated with bfa persist over two weeks? 2. what is the pain medication usage during and after intervention treatments? 2. to explore the effectiveness of bfa on trunk flexion mobility and balance. 1. does pain reduction improve trunk flexion and balance? 2. does improved truck flexion mobility and balance contribute to increased physical activity?


Eligibility criteria:
inclusion criteria: * diagnosis of lbp (pain for \> 4 weeks, with or without radiating nerve pain * age 18 to 50 years * active duty military, public health service, or coast guard (guard and reserve on active orders) * pain score 3/10 or higher as patient reported on the dvprs * modi score ≥ 20% * no anticipated prolonged temporary duty, deployment, or vacation within the next month. exclusion criteria: * any severe comorbidity * lbp neurologic "red flags" indicating serious spinal pathology (i.e. bowel or bladder dysfunction) * auricular acupuncture in the past 6 months * use of steroids in the month prior to the study * hemorrhagic disorders * malignancy * unexplained weight loss * severe scoliosis or congenital spine disorder * back pain because of a visceral problem (e.g. endometriosis) * under surgeon's care for back surgery within the last 12 months * balance disorder * pregnancy or suspected pregnancy (last menstrual period will be reported by the patient) * aversion to needles * previous keloid scar formation * active infection on the ear * bleeding disorder * metal allergy * mental health diagnosis requiring medication (depression, ptsd, etc) * untreated sleep apnea or other sleep disorders
effects of proteins fraction derived from milk on osteoporosis prevention

Conditions: Osteoporosis

Summary: osteoporosis is defined as a systemic skeletal disease characterised by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture. osteoporosis is a serious public health problem that is responsible for approximately 3 million women with osteoporosis in france, with approximately 150,000 cases per year occurring in vertebral fractures, of which only one third would be diagnosed and 50,000 hip fractures (causing death in 20% of cases). the frequency of the disease increases with age, particularly among women: 10% among women aged 60 years and 20% among women aged 65 and 40% among women aged 75. at menopause, oestrogen deficiency causes alterations of the immune system, decreased bone formation, microarchitectural deterioration and a decrease in bone mass. various factors may contribute to this decrease in bone density such as diet, lifestyle, or the genetic background. according to prospective studies, an overexpression of 135% of hip fractures is expected at european level in 50 years. therefore, it is interesting to develop new prevention approaches aimed at maintaining the healthy aging population. nutritional researches can consider setting up a real prevention. studies suggest that specific milk protein fraction contain factors able to promote bone formation, inhibit bone resorption in vitro. in animal model, they showed that the specific fraction prevents bone loss in aged ovariectomised rats by reducing bone resorption. furthermore, in human volunteers, a supplementation with the specific milk protein fraction maintains balanced bone remodelling and increase bone mineral density. for example, in healthy postmenopausal women, it has been reported that a mean rate of gain of lumbar bmd in the mpf group (1.21%) was significantly higher than in placebo group (-0.66%; p\<0.05). the objective of this study is to assess the efficacy of daily consumption of the milk proteins fraction on bone mineral density improvement in healthy postmenopausal women.


Eligibility criteria:
inclusion criteria: * caucasian female * natural or surgical menopause between 1 and 5 years * aged between 50 to 65 years * bmi between 19 and 30 kg/m² exclusion criteria: * medications: oral steroidal anti-inflammatory, anti-osteoporotic treatment, hormone replacement therapy * low bone mineral density (t-score\<-3 * diseases affecting bone metabolism(paget's disease, cushing's disease, thyroid disease...) * intolerance or allergy to milk proteins and allergy to soy or soy lecithin * heavy smoking * excessive alcohol drinking * intensive sports practice according to the investigator
predict adverse events by covid-19 nephritis

Conditions: Covid-19

Summary: this non-interventional, observational study retrospectively (and in parts prospectively) investigates, if a covid-19 associated nephritis, diagnosed by urine-dipstick and further urine-analyses on addmission, can help to predict later complications, adverse outcomes and later need for icu-capacity in covid-19 patients as well as can guide preventive strategies.

parameters predicting risks for covid-19 patients are urgently sought. the current study investigates, if covid-19 associated nephritis indicating systemic cappillary leak syndrome/severe nephrotic syndrome could be the major driver for complications, predictor for respiratory failure and later need for icu, and death. this study intends to generate an algorithm for university hospitals, which allows early detection of covid-19 associated nephritis and to classify the risk for respiratory decompensation by quantification of severity of nephrotic syndrome. the rationale of the observational study can be explained by the hypothesis that covid-19 causes nephritis: podocytes express high levels of ace2, which makes the glomerulus to a target for covid-19. other zoonoses, such as hanta-virus, are a well described cause of nephrotic syndrome inducing cardiopulmonary syndrome. life-threatening complications of severe nephrotic syndrome are well known as are preventive therapies. covid-19 icu patients with nephritis have 1. pulmonary interstitial edema, possibly also due to capillary leak/ nephrotic syndrome; 2. immune-incompetence, due to renal loss of immunoglobulins; 3. circulatory insufficiency, due to hypalbuminemia (which might explain sudden deaths in the geriatric population); 4. less response to some medications caused by impaired plasma protein binding of drugs due to hypalbuminemia and renal loss; 5. thromboembolic events, due to antithrombin-deficiency (which might explain lethality in oligo-symptomatic young patients). in conclusion, ace2 in the respiratory tract is the gateway for covid-19 for infection, however, the study postulates that covid-19 associated nephritis and severe cappillary leak/nephrotic syndrome is a major driver of adverse outcome. if confirmed by others, these findings and algorithm would allow early prediction of later need for icu-capacity, better allocation of patients for clinical trials, and preventive strategies focused on the nephrotic syndrome including treatment, which can save lives. same might apply for risk-evaluation of outpatients.

Eligibility criteria:
inclusion criteria: 1. approved covid-19 diagnosis (by pcr or ct-scan); 2. urine status during hospital stay 3. patient expressed willingness to participate in observational studies during hospital admission. exclusion criteria: 1) patient expressed unwillingness to participate in observational studies during hospital admission.
a study of dementia and neurological problems in hiv infected patients who are participating in actg a5175

Conditions: HIV Infections

Summary: the purpose of this study is to determine how often dementia and other neurological problems occur in people with hiv. participants of actg a5175 will enroll in this study.

both the central and peripheral nervous systems (cns and pns) are affected by hiv; however, the causes of neurotoxicity in hiv infected patients are unknown. initial data indicate that as many as 40% of patients with hiv develop some form of dementia. other common neurological problems observed in hiv patients are peripheral neuropathy and opportunistic infections of the cns. most antiretroviral drugs used in the treatment of hiv have poor penetration into the cns, which may explain how hiv persists in the cns and contributes to the prevalence of dementia and other neurological disorders in hiv infected patients. this study will examine the prevalence of dementia and other neurological disorders in participants in actg a5175, "once-daily pi/nnrti therapy combinations for treatment naive, hiv infected patients in resource-limited conditions." the study will last approximately 2.5 to 3 years. participants will undergo neurological examinations and neuropsychological assessments at entry to both steps of actg a5175 and before the administration of the new antiretroviral regimen, then every 24 weeks until they discontinue actg a5175. physicians will make targeted diagnoses at each study visit.

Eligibility criteria:
inclusion criteria: * hiv-1 infected * prior antiretroviral therapy for less than 7 days any time prior to study entry * cd4 count less than 300 cells/mm3 * willing to use acceptable means of contraception * plans to stay in the area for the duration of study participation * willing to adhere to study follow-up schedule for actg a5175 and this study * have not begun actg a5175 antiretroviral therapy, but planning to start therapy after enrolling in this study exclusion criteria: * any active severe psychiatric illness (e.g., schizophrenia, severe depression, severe bipolar affective disorder) that, in the opinion of the site investigator, may interfere with the study results * current drug or alcohol abuse that, in the opinion of the site investigator, would interfere with study requirements * serious illness or hospitalization that, in the opinion of the site investigator, may interfere with the study results * any condition that, in the opinion of the site investigator, would interfere with study requirements

Keywords: acute infection treatment naive
rutgers pilot for predict- patient poc test

Conditions: SARS CoV 2 Infection

Summary: a pilot study was initiated to assess feasibility of testing asymptomatic dental patients presenting to the oral medicine clinic at rutgers school of dental medicine for sars-cov-2 viral antigen using a point-of-care (poc) rapid antigen test. 14 subjects with upcoming appointment at the oral medicine clinic, rutgers school of dental medicine, with no history of documented covid-19 infection or viral exposure, were enrolled in a study that interrogated patients' perceptions of safety and feedback regarding their testing experience. all 14 patients expressed initial interest, however, 10 patients completed informed consent and completed study procedures. institutional clinical laboratory improvement amendments (clia) certification of waiver was obtained prior to conducting the study. communicable diseases reporting and surveillance system (cdrss) registration and training were completed to enable reporting results of the poc test.

a pilot study was initiated to assess feasibility of testing asymptomatic dental patients presenting to the oral medicine clinic at rutgers school of dental medicine for sars-cov-2 viral antigen using a point-of-care (poc) rapid antigen test. 14 subjects with upcoming appointment at the oral medicine clinic, rutgers school of dental medicine, with no history of documented covid-19 infection or viral exposure, were enrolled in a study that interrogated patients' perceptions of safety and feedback regarding their testing experience. all 14 patients expressed initial interest, however, 10 patients completed informed consent and completed study procedures on their appointments, the remaining 4 patients did not present for their appointment. following initial interest in participation over the phone, the subjects completed a pre-visit survey prior to their upcoming appointment. the day prior to their visit, a phone triage was completed and repeated as they checked in for their appointment. a nasal sample was collected and processed using the fda eua authorized rapid antigen test bd veritor plus analyzer, bd sciences. an end-of-study survey was collected to assess patients' feedback about their experience and their perception of safety.

Eligibility criteria:
inclusion criteria: * dental patients with upcoming appointment at the oral medicine clinic at rutgers school of dental medicine exclusion criteria: * patients previously participating in the study * patients unwilling to have their de-identified data made available to researchers

Keywords: screening point-of-care testing asymptomatic patients perception of safety feasibility
visual telerehabilitation in amd patients

Conditions: Macular Degeneration

Summary: following the degeneration of the macula and the loss of central vision, the patients naturally relocate the fixation point for high visual acuity peripherally, in an eccentric and healthy part of the retina (prl), to compensate for visual impairments. however, in many cases, the prl lands on a sub-optimal retinal area and becomes useless. modern low-vision rehabilitation procedures for amd patients include biofeedback training (bft) to relocate the prl to a healthy retinal patch and acquire better fixation skills. this study seeks to combine bft with home-based immersive virtual-reality audiovisual stimulation and measure feasibility and potential effectiveness on oculomotor control and visual perception.


Eligibility criteria:
inclusion criteria: * dry-amd. * bcva \> 20/160. * ability to follow the visual and auditory stimuli and training instructions. * auditory test positive at 50hz 25-60dbhl. * home wi-fi access. exclusion criteria: * wet amd. * both eyes with media opacity that impairs microperimetry testing. * inability to perform during testing and training. * psychoactive drugs consumption. * 3 consecutive vrise scores \< 25 at inclusion. * history of vertigo or dizziness * prior vision rehabilitation interventions.

Keywords: visual rehabilitation oculus go virtual-reality biofeedback
a follow-on safety study of cdp870 in subjects with crohn's disease (cd) who have completed a 26-week double blind study cdp870-031 [nct00152490] or cdp870-032 [nct00152425]

Conditions: Crohn's Disease

Summary: an open-label follow-on safety study of cdp870 (400 mg every 4 weeks) in patients with crohn's disease who have completed a 26-week blinded study (cdp870-031 \[nct00152490\] or cdp870-032 \[nct00152425\]).


Eligibility criteria:
inclusion criteria: * participation in either of the cdp870-031 \[nct00152490\] or cdp870-032 \[nct00152425\] clinical studies in which the subject completed the trial at week 26. subjects may have received active or placebo or both treatments in the prior study * subjects must be able to understand the information provided to them and give written informed consent exclusion criteria: * any exclusion criterion that would have prevented the subject's participation in the qualifying pivotal study cdp870-031 \[nct00152490\] or cdp870-032 \[nct00152425\], although the criterion that excludes previous participation in a clinical trial of certolizumab pegol does not apply. in addition there are no limits on the clinical disease activity index (cdai) score at entry

Keywords: certolizumab pegol cimzia cdp870 czp
evaluation of neurological status and school readiness in preterm preschoolers

Conditions: School Readiness

Summary: beginning school is an important milestone for children. children's readiness for school involves cognitive, physical, and emotional development. while the majority of children born preterm are able to transition from preschool to kindergarten with little difficulty, some children experience challenges during this time. factors that negatively influence children's success in kindergarten include their age, socioeconomic status, neurological status and their ability to interpret sensory information from their environment. this study was planned to explain the relationship between the primary school readiness and the neurological status of preterm born children.

a convenience of preterm and term preschoolers recruiting from gazi university, faculty of health science, department of physiotherapy and rehabilitation. each group contains 30 children. first, sociodemographic information and histories of children are obtaining. ages and contact information of the parents are recording. prenatal and natal risk factors of the mothers are querying. gestational ages and height, weight, and head circumferences of babies at birth are recording. number of pregnancies, live births and abortions, type of delivery, multiple pregnancies for mothers as well as consanguinity between parents are asking. marmara primary school readiness scale is using to evaluate mental-language development, socio-emotional development, physical development, self-care skills,math skills, science skills, voice exercises, line exercises and labyrinths. sensory profile caregiver questionnaire screen for the senses (sensory processing), adjustment (modulation), behavioral and emotional responses. the touwen examination (neurological examination) is using to evaluate posture in various positions, muscle tone, dyskinesias, range of motion, reflexes, sensory function and cranial nerve function as well as developmental items, i.e. the items dealing with coordination, fine manipulative abilities and associated movements. all examination wiil be finished in the same day.

Eligibility criteria:
inclusion criteria: * no neurological diagnosis * gestational age \< 37 weeks * 60-78 months of age exclusion criteria: * have a neurological diagnosis (such as cerebral palsy) * grade iii or grade iv intraventricular hemorrhage * have undergone major surgery in neonatal period * mental retardation

Keywords: preterm neurological status school readiness
retrospective analysis of spray skin treats for severe burns

Conditions: Morality; Skin Graft Complications

Summary: this study investigated the efficacy of novel approach spray skin for extensive severe burns treatment.

burns are a global public health problem. this study investigated the efficacy of novel approach spray skin (autologous skin cell suspension combined with split-thickness skin grafting, stsg) for extensive severe burns treatment. we performed a real-world retrospective analysis of extensive burns patients (\> 50% tbsa) from our hospital last 10 years.

Eligibility criteria:
inclusion criteria: * patients with \> 50% tbsa exclusion criteria: * died within 1 week after admission * admitted to hospital more than 1 week after injury

Keywords: spray skin, severe burn, microskin grafting
a pharmacokinetic study of once daily efavirenz 400 mg versus 600 mg in thai hiv-1 infected subjects

Conditions: HIV Infections

Summary: a pharmacokinetic study of once daily efavirenz 400 mg versus 600 mg in thai hiv-1 infected subjects.

efavirenz pharmacokinetic evaluation supports once-daily dosing (t1/2 is 10-52 hours). the recommended dosage of efavirenz in combination with nucleoside reverse transcriptase inhibitor (nrti) and/or protease inhibitor (pi) is 600mg orally, once daily. in thai populations, many arv levels are very high. we believe that 600 mg efavirenz is too high for thai people and would like to see the pharmacokinetic data and safety and efficacy of efavirenz at 400 mg.

Eligibility criteria:
inclusion criteria: * age \> 18 years of age or older with hiv-1 infection * who are on stable pi-based highly active antiretroviral therapy and have hiv-1 rna \<50 copies/ml within 6 months. * no active opportunistic infection. * sexually active subjects must be willing to use an effective form of birth control. * able to provide written informed consent. exclusion criteria: * pregnant or breast-feeding females are excluded. * inability to understand the nature and extent of the study and the procedures required. * alt/ ast more than 5x upper limit * relevant history or current condition, illness that might interfere with drug absorption, distribution, metabolism or excretion. * use of concomitant medication that may interfere with the pharmacokinetics of efavienz * history of sensitivity/idiosyncrasy to the drug or chemically related compounds which may be employed in the study. * active drug abuse

Keywords: once daily efavirenz 400 mg pk once daily efavirenz 400 mg versus 600 mg treatment experienced
status of management of surgery in beijing during covid-19

Conditions: Gastric Cancer; Colorectal Cancer; Gastrointestinal Disease

Summary: this is a multi-centered, retrospective, observational study aimed at observing the current status of the management of gastrointestinal surgery during the covid-19 pandemic, particularly the changes on surgery protocols and other key aspects of surgical workflow, so as to share experience with colleagues both domestic and abroad.


Eligibility criteria:
inclusion criteria: * all patients arriving at surgical emergency and all patients receiving gastrointestinal surgeries in participating centers from 2020.1.1\~2020.3.31. exclusion criteria: * none